Leslie Fecher

  • 2328 Citations
  • 13 Scopus h-Index

Fingerprint Fingerprint is based on mining the text of the persons scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 1 Similar Profiles
Melanoma Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Skin Medicine & Life Sciences
Clinical Trials Medicine & Life Sciences
Mitogen-Activated Protein Kinase Kinases Medicine & Life Sciences
Merkel Cell Carcinoma Medicine & Life Sciences
Hydroxychloroquine Medicine & Life Sciences
Mutation Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 2016 2024

Research Output 2007 2017

Merkel Cell Carcinoma
Clinical Trials
1 Citations

Acute visual loss after ipilimumab treatment for metastatic melanoma

Wilson, M. A., Guld, K., Galetta, S., Walsh, R. D., Kharlip, J., Tamhankar, M., McGettigan, S., Schuchter, L. M. & Fecher, L. A. Oct 18 2016 In : Journal for ImmunoTherapy of Cancer. 4, 1, 66

Research output: Contribution to journalArticle

Optic Neuritis
5 Citations

Metastatic Merkel cell carcinoma response to nivolumab

Walocko, F. M., Scheier, B. Y., Harms, P. W., Fecher, L. A. & Lao, C. D. Nov 15 2016 In : Journal for ImmunoTherapy of Cancer. 4, 1, 79

Research output: Contribution to journalArticle

Merkel Cell Carcinoma
Immune Evasion
Immunoglobulin G
Clinical Trials
42 Citations

Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial

Weber, J. S., Gibney, G., Sullivan, R. J., Sosman, J. A., Slingluff, C. L., Lawrence, D. P., Logan, T. F., Schuchter, L. M., Nair, S., Fecher, L., Buchbinder, E. I., Berghorn, E., Ruisi, M., Kong, G., Jiang, J., Horak, C. & Hodi, F. S. Jul 1 2016 In : The Lancet Oncology. 17, 7, p. 943-955 13 p.

Research output: Contribution to journalArticle

Random Allocation
Disease Progression
2 Citations

Advanced basal cell carcinoma, the hedgehog pathway, and treatment options – Role of smoothened inhibitors

Fecher, L. A. & Sharfman, W. H. Nov 6 2015 In : Biologics: Targets and Therapy. 9, p. 129-140 12 p.

Research output: Contribution to journalReview article

Basal Cell Carcinoma
Patient Care Management